- Home
- MCHX vs ADAG Comparison
MCHX vs ADAG Comparison
Compare MCHX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCHX | ADAG |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 84.8M |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MCHX | ADAG |
|---|---|---|
| Price | $1.68 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 17.3K | ★ 53.1K |
| Earning Date | 11-13-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,494,000.00 | $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | $6.70 | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $1.30 |
| 52 Week High | $2.31 | $3.16 |
Technical Indicators
Market Signals| Indicator | MCHX | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 46.90 |
| Support Level | $1.60 | $1.76 |
| Resistance Level | $1.73 | $1.93 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 20.01 | 50.00 |
Price Performance
Historical ComparisonAbout MCHX Marchex Inc. Class B
Marchex Inc harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales, and marketing teams to optimize customer journey experiences across communications channels, enabling enterprise strategies, empowering businesses to increase revenue through informed decision-making and strategic execution.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.